Anatara Lifesciences Ltd

ANR

AU000000ANR0

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 01:36:08 2024-05-23 EDT			5-day change	1st Jan Change
0.044 ^AUD	+4.76%		+12.82%	+100.00%

05-01	Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	MT
04-09	Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	MT

Anatara Lifesciences Limited Announces Resignation of David James Stuart Hetzel as Director

November 12, 2018 at 05:40 pm

Anatara Lifesciences Limited announced the resignation of David James Stuart Hetzel as director, effective November 12, 2018.

Latest news about Anatara Lifesciences Ltd

Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	04-30	MT
Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	04-08	MT
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer	12-08	MT
Anatara Lifesciences Ltd Announces Board Changes	23-10-01	CI
Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial	23-09-28	MT
Anatara Lifesciences Finalizes Patients for Irritable Bowel Syndrome Clinical Trial Stage One	23-08-30	MT
Anatara Lifesciences Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-23	CI
Anatara Lifesciences Receives R&D Tax Rebate; Shares Up 3%	23-08-14	MT
Anatara Lifesciences Ltd Announces Registered Office Change	23-04-19	CI
Anatara Lifesciences Provides Update on the Gastrointestinal Reprogramming(Garp) Trial for IBS	23-03-09	CI
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Anatara Lifesciences Ltd Announces board Changes	22-12-06	CI
Anatara Lifesciences Raising Funds for Patient Trial, Future Project Acquisitions	22-10-21	MT
Anatara Lifesciences Receives More than $310,000 R&D Tax Rebate	22-10-04	MT
CSIRO Halts Psychological Functioning Trial for Dietary Supplement	22-10-03	MT
Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial	22-10-02	CI
Anatara Lifesciences Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Anatara Lifesciences Modifies Protocol for Upccoming Gastrointestinal Disease Trial	22-08-11	MT
Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer	22-06-21	CI
Anatara Lifesciences Limited Announces to Provide an Update on the Progress of Clinical Trials in Irritable Bowel Syndrome and Psychological Functioning	22-06-21	CI
Anatara Lifesciences Expands Criteria for Irritable Bowel Trial	22-05-20	MT
Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype	22-05-19	CI
Anatara Lifesciences CEO to Step Down	22-05-05	MT
Anatara Lifesciences Limited Announces Chief Executive Officer Changes	22-05-04	CI

Chart Anatara Lifesciences Ltd

Duration

Period

More charts

Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANATARA LIFESCIENCES LTD	+100.00%	5.33M
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B